Jyothi Dodlapati, MD
Medical Oncology · Harker Heights, TXNPI 1467402602
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 94.3% of the total across 53 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 31 manufacturers, the largest accounting for just 11.5% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $713, 6.1 times the $117 reported in 2020. That places this record below the midpoint for medical oncology clinicians in TX, where the typical reported total is $4,372.
Across 53 payments — averaging $32.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$198
- E.r. Squibb & Sons, L.L.C.$188
- ADC Therapeutics America, Inc.$123
- Boehringer Ingelheim$116
- Eisai Inc.$108
- Novartis$96
- plus $893 from 25 others
Across 12 payments — averaging $10,070 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$95K
- Bristol Myers Squibb$21K
- Exelixis Inc.$5K
What the payments were for
- Food & beverage$1,62494%
- Education$986%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 5 | $198 |
| E.r. Squibb & Sons, L.L.C. | 2 | $188 |
| ADC Therapeutics America, Inc. | 1 | $123 |
| Boehringer Ingelheim | 1 | $116 |
| Eisai Inc. | 5 | $108 |
| Novartis | 5 | $96 |
| Medtronic | 1 | $96 |
| Exelixis Inc. | 1 | $93 |
| Agios Pharmaceuticals, Inc. | 1 | $85 |
| Taiho Oncology, Inc. | 3 | $59 |
| Bayer | 2 | $47 |
| Johnson & Johnson | 2 | $44 |
| Merck | 2 | $44 |
| AVEO Pharmaceuticals, Inc. | 2 | $37 |
| Beigene USA, Inc. | 2 | $36 |
| Bristol Myers Squibb | 2 | $30 |
| GSK | 2 | $30 |
| Daiichi Sankyo Inc. | 1 | $27 |
| Geron Corporation | 1 | $26 |
| Caris MPI, Inc. | 1 | $26 |
| Janssen Scientific Affairs, LLC | 1 | $25 |
| Amgen | 1 | $22 |
| Gilead | 1 | $21 |
| Array Biopharma Inc | 1 | $21 |
| Pfizer | 1 | $19 |
| Incyte Corporation | 1 | $19 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $18 |
| Lilly USA, LLC | 1 | $18 |
| Regeneron Healthcare Solutions, Inc. | 1 | $17 |
| Astellas Pharma US Inc | 1 | $17 |
| Stemline Therapeutics Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,722 in reported general payments places this provider in the 30th percentile of 495 medical oncology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Hydroxyurea | 17 | $427 |
| Ondansetron OdtOndansetron | 11 | $398 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 13 | $186 |
| Anastrozole | 16 | $113 |
| Potassium Chloride | 17 | $75 |
Paid to pharmacies, not to this prescriber.
Other medical oncology in Harker Heights
- Moshe LevyDallas$5.1M
- Suresh RatnamMcAllen$3M
- Roy HerbstHouston$1.9M
- Andrew WhiteleyDallas$1.7M
- Eric NadlerDallas$1.6M
- Vijay GunugantiSan Antonio$1.5M
- Sue EckhardtAustin$1.5M
- Joyce O'ShaughnessyDallas$1.3M
- Ronan KellyDallas$1.1M
- Maen AbdelrahimHouston$999K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.